+ Filter
Loading...
Custom Services order now ship next day

BTLA

Loading...

Anti-BTLA Products

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs offers a comprehensive range of anti-BTLA recombinant antibodies, engineered to deliver exceptional specificity and affinity for cutting-edge immunological research and therapeutic development. Our products undergo rigorous validation to ensure optimal performance across diverse assays, providing researchers with the precision and reliability required for their critical studies.

BTLA: An Attractive Target for Cancer Therapy

The B and T lymphocyte attenuator (BTLA) is a critical cosignaling molecule within the CD28 superfamily, sharing structural and functional similarities with PD-1 and CTLA-4. BTLA is expressed in most lymphocytes and plays a key role in immune regulation by inhibiting the activation and proliferation of B and T cells. Recent research has highlighted BTLA’s involvement in a variety of pathological processes, including cancer, inflammatory diseases, autoimmune disorders, infectious diseases, and transplant rejection. Consequently, the development of antibodies targeting BTLA presents a promising avenue for cancer treatment.

Alternative Names

B And T Lymphocyte Associated; B- And T-Lymphocyte-Associated Protein; B- And T-Lymphocyte Attenuator; CD272 Antigen; BTLA1; CD272.

Background

This gene encodes a member of the immunoglobulin superfamily. The encoded protein contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. Alternative splicing results in multiple transcript variants. Polymorphisms in this gene have been associated with an increased risk of rheumatoid arthritis.

Protein class

CD markers

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Cell type enriched (B-cells)

Immune cell specificity

Group enriched (naive B-cell, memory B-cell, plasmacytoid DC)

Cell line specificity

Cell line enhanced (U-698)

Interaction

Interacts with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:12796776, PubMed:14652006). Interacts with TNFRSF14/HVEM (via cysteine-rich domain 1) (PubMed:15568026, PubMed:18193050, PubMed:19915044).

Molecular function

Receptor

More Types Infomation

Anti-BTLA rAb Products

Creative Biolabs offers a comprehensive selection of anti-BTLA recombinant antibodies designed to specifically target and inhibit BTLA. These high-quality antibodies are characterized by their exceptional affinity and specificity, ensuring precise binding and inhibition. Available in various formats to meet diverse research needs, our anti-BTLA antibodies are ideal for a wide range of immunological studies.

Table 1. Featured anti-BTLA recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
HPAB-1605LY Human Anti-BTLA Recombinant Antibody Human Humanized IgG ELISA, FC
HPAB-M0448-YC Mouse Anti-BTLA Recombinant Antibody Human Mouse IgG FC
HPAB-0196-WJ Mouse Anti-BTLA Recombinant Antibody Human Mouse IgG1 ELISA, FC, WB, Neut
TAB-1309CL Human Anti-BTLA Recombinant Antibody Cynomolgus, Human Human IgG Inhib
TAB-1310CL Human Anti-BTLA Recombinant Antibody Cynomolgus, Human Human IgG Block

Creative Quality Control

Creative Biolabs is dedicated to providing premium anti-BTLA recombinant antibodies for cutting-edge immunological research. Our advanced facilities and stringent quality assurance protocols guarantee the creation of antibodies that possess superior characteristics. At the same time, our dedicated scientific team actively oversees and refines our production methods to uphold the utmost standards in biotechnological innovation.

Fig.1 SDS-PAGE analysis. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-BTLA antibody
(Cat# TAB-1310CL, Creative Biolabs).

Fig.2 HPLC analysis. (Creative Biolabs Original)Fig.2 HPLC analysis of anti-BTLA antibody
(Cat# TAB-1310CL, Creative Biolabs).

Fig.3 SDS-PAGE analysis. (Creative Biolabs Original)Fig.3 SDS-PAGE analysis of anti-BTLA antibody
(Cat# TAB-1309CL, Creative Biolabs).

Customer Reviews

Excellent
Fi***o
Mouse Anti-BTLA Recombinant Antibody (HPAB-M0448-YC) (HPAB-M0448-YC)
I've been using Creative Biolabs' anti-BTLA antibody for my research and have been impressed by its quality. The antibody's specificity and affinity are exceptional, and their customer service is outstanding. I highly recommend Creative Biolabs to anyone looking for high-quality anti-BTLA antibodies.
13/May/2021
Excellent
De***h
Human Anti-BTLA Recombinant Antibody (HPAB-1605LY) (HPAB-1605LY)
I've been incredibly impressed with Creative Biolabs' anti-BTLA recombinant antibodies. Their wide selection, coupled with exceptional affinity and specificity, has been instrumental in advancing my research and clinical projects. The availability of multiple formats has ensured flexibility and reliability in my experimental setups. I wholeheartedly recommend Creative Biolabs to any researcher focused on BTLA inhibition.
21/Oct/2022
Excellent
Ja***e
Mouse Anti-BTLA Recombinant Antibody (HPAB-0194-WJ) (HPAB-0194-WJ)
I recently had the opportunity to use Creative Biolabs' anti-BTLA recombinant antibody, and I am thoroughly impressed with the results. The antibodies exhibited exceptional affinity and specificity, seamlessly binding to the BTLA target with high precision. Additionally, the range of available formats enabled me to select the one that best fit my experimental design. The comprehensive selection provided by Creative Biolabs ensured that I had access to the best options for my research needs. The performance and reliability of these antibodies have significantly advanced my work, and I would highly recommend Creative Biolabs to fellow researchers.
7/May/2023

rAb Production

Our state-of-the-art anti-BTLA recombinant antibody platform leverages genetically modified cells to generate high-quality antibodies specifically targeting the BTLA protein. This innovative system facilitates scalable and efficient production, providing a reliable supply for both research and therapeutic uses.

Featured Anti-BTLA Recombinant Antibody Production PlatformsFig.4 Milligram-scale. (Creative Biolabs Original)
Fig.4 Milligram-scale anti-BTLA recombinant antibody production.

Fig.5 Gram-scale. (Creative Biolabs Original)Fig.5 Gram-scale anti-BTLA recombinant antibody production.

rAb Modalities

Creative Biolabs provides an extensive selection of premium anti-BTLA recombinant antibodies in multiple formats.

Fig.6 BTLA antibody production and modalities. (Creative Biolabs Original)Fig.6 Full-length anti-BTLA recombinant antibody production and modalities.

BTLA-Targeted Drug Information

Table 2. Public drug targeting BTLA.

Highest Phase Mechanism of Action Product Category Condition Organization
Phase III Anti-BTLA (B- and T-lymphocyte Attenuator)
Immune Checkpoint Inhibitors
Cancer Immunotherapy
Humanized Monoclonal Antibodies
Cancer, head and neck (squamous cell carcinoma)
Cancer, lung
Cancer, lung (non-small cell) (NSCLC)
Cancer, lung (small cell) (SCLC) (extensive)
Cancer, lung (small cell) (SCLC) (limited)
Cancer, nasopharynx
Cancer, solid tumor
Hodgkin lymphoma (classical)
Lymphoma
Shanghai Junshi Biosciences (Originator)
Phase II Anti-BTLA (B- and T-lymphocyte Attenuator)
Immune Checkpoint Inhibitors
Antibodies Atopic dermatitis
Inflammatory disorders
AnaptysBio (Originator)
Phase I Anti-BTLA (B- and T-lymphocyte Attenuator)
B- and T-Lymphocyte Attenuator (BTLA) Activators
Immune Checkpoint Inhibitors
Agonist Antibodies Autoimmune disease
Rheumatoid arthritis
Systemic lupus erythematosus
Gilead (Originator)
Discontinued Anti-BTLA (B- and T-lymphocyte Attenuator)
Immune Checkpoint Inhibitors
Agonist Antibodies
Monoclonal Antibodies
Inflammatory disorders
Plaque psoriasis
Psoriasis
Rheumatoid arthritis
Systemic lupus erythematosus
Lilly (Originator)
Preclinical B- and T-Lymphocyte Attenuator (BTLA) Activators Fusion Proteins
Polypeptides, from 41 AA
Inflammatory disorders Avalo Therapeutics
Sanford Burnham Prebys Medical Discovery Institute (Originator)
Preclinical Cell-Based Gene Therapy Diabetes type 1 Guiyang First People's Hospital (Originator)
Biological Testing BTLA Expression Inhibitors CRISPR/Cas-Mediated Edited Cell Therapy
Mesenchymal Stem Cells
MicroRNA
Oligoribonucleotide (RNA)
Short Hairpin RNA (shRNA)
Cancer, colorectal
Cancer, liver (hepatocellular carcinoma)
Melanoma
Future Homo Sapiens Regenerative Medicine Research Institute (guangzhou) (Originator)
Biological Testing Anti-BTLA (B- and T-lymphocyte Attenuator)
Immune Checkpoint Inhibitors
Antibodies
Antibody Gene Therapy
Cancer Immunotherapy
CRISPR/Cas-Mediated Edited Cell Therapy
Mesenchymal Stem Cells
Stem Cell-Based Gene Therapy
Cancer
Cancer, colorectal
Cancer, liver
Melanoma
Future Homo Sapiens Regenerative Medicine Research Institute (guangzhou) (Originator)
Biological Testing BTLA Expression Inhibitors RNA Interference
Single-stranded oligoribonucleotide (RNA)
Immunological Disorders Shenzhen Biocan Technologies (Originator)
Biological Testing BTLA Expression Inhibitors Double-stranded oligoribonucleotide (RNA)
Short Hairpin RNA (shRNA)
Autoimmune disease
Cancer
Infections
Transplant rejection
Shenzhen Biocan Technologies (Originator)

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Need a unique antibody tailored to your specific research needs? Please contact us to design and produce custom anti-BTLA antibodies to meet your exact requirements.

Go to compare

Go to compare